These disclosures are from 13D submitted to the Securities and Exchange Commission. 13Ds are filed within 10 days after the company reaches more than 5% in each class of securities of the company. Subsequent changes in holdings or intentions must be reported in amended dossiers. This material is from February. March 24 to 2, 2022. Source: InsiderScore.com
LivePerson Record (LPSN)
Right board value revealed the ownership of 7,005,000 shares of the mobile communications company, equivalent to 9.7% of the outstanding shares. On Feb. At 25, Starboard Value presented three nominees for election to the LivePerson board at its upcoming annual shareholders’ meeting in 2022. This announcement followed the announcement of LivePerson’s earnings after the end of February. 24. The technology firm has driven revenue for the second quarter and all of 2022 below forecasts, sparking a sell-off that wiped out about a third of LivePerson’s market value by the next day. Since then, the stock has recovered from a multiple decline from
JP Morgan, B. Riley Securities, Cantor Fitzgerald and others.
Cytek Biosciences Record (CTKB)
RA Capital increased its interest in the manufacturer of cellular analysis equipment to 11,082,163 shares. RA Capital bought 1,475,135 shares of Cytek Biosciences in February. From 14 to Feb. 28 at prices ranging from $ 12.97 to $ 14.99. RA Capital now has an 8.3% stake in biotechnology. Director Tess Cameron represents RA Capital on the board of Cytek Biosciences.
Amicus Therapeutics (FOLDING)
Susceptible advisors raised its position in the biopharmaceutical company to 27,356,043 shares. Perceptive bought 787,498 and 208,904 shares of Amicus Therapeutics in February. March 28 and 1, respectively, at prices from $ 7.96 to $ 8.41. Perceptive already owns 9.7% of Amicus. Last month, Amicus and a special purpose acquisition company
ARYA Sciences Acquisition Corp. IVs mutually agreed to end a business combination that would create a new Amicus biotechnology, Caritas Therapies. Going forward, Perceptive will now report on the 13G chart as a passive investor. It also “intends to buy more” shares of Amicus, but has no obligation for Perceptive to do so.
Reduction of holdings
Occidental Petroleum (OCSI)
of Carl Aikan Icahn Capital reduced its interest in the oil and gas explorer by nearly a third to 32,586,486 shares. Icahn Capital has sold 26,941,467 shares of Occidental Petroleum since February. March 28 to 2 at prices ranging from $ 41.84 to $ 48.34. Also on Feb. On the 28th, Icahn Capital sold 476,719 warrants to Occidental Petroleum, exercising at a price of $ 22, at a price of $ 22.10 per share. No reason was given for the sales, which left Icahn Capital with a 3.4% stake in Occidental.
As Icahn Capital no longer owns 5% of the company, it is not required to report future sales that do not force it to reach this level. Energy stocks rose at higher commodity prices, and Occidental shares jumped more than 60% in 2022.